A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection

A Phase 1b, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With RSV Infection

The purpose of this study is to evaluate pharmacokinetics, safety, tolerability, antiviral activity, and impact on the clinical course of Respiratory Syncytial Virus (RSV) infection after multiple oral doses of JNJ-53718678 at different doses and/or dosing regimens in infants (greater than [>] 1 month to less than or equal to [<=] 24 months of age) who are hospitalized with RSV infection.

Study Overview

• Status: Terminated
• Conditions: Virus Diseases; Respiratory Syncytial Virus Infections
• Intervention / Treatment: Drug: JNJ-53718678; Drug: Placebo

Detailed Description

This is a Phase 1b, randomized (study medication assigned to participants by chance), partially double-blind (neither physician nor participant knows the identity of the assigned treatment), placebo-controlled, multicenter, multiple ascending dose study of JNJ 53718678 in infants (greater than [>] 1 month to less than or equal to [<=] 24 months of age) who are hospitalized with RSV infection. The duration of study will be approximately 4 weeks for each participant excluding screening period. In Part 1 of study, minimum total number of 42 participants will be divided in 3 cohorts: Age group 1 (Cohorts 1a-1e) (greater than or equal to [>=] 6 months and less than or equal to [<=] 24 months of age), Age group 2 (Cohorts 2a-2e)(>=3 months and less than [<] 6 months of age) and Age group 3 (Cohorts 3a-3e) (greater than [>] 1 month and <3 months of age). Each age group will consist of a minimum of 3 cohorts with the possibility to add 2 more per age group (Cohorts a through e) in which different doses and/or dosing regimens will be evaluated. Each cohort will consist of 5 participants (4 participants receiving JNJ-53718678 and 1 participant receiving placebo for 7 days), except for the first cohort of each age group which will contain only 4 participants (4 participants receiving JNJ 53718678). In Part 2 of the study, all age groups will be included in a single cohort, Cohort f, in which the selected dose regimen determined during Part 1 of the study will be used for each of the 3 age groups. A minimum of approximately 18 (12 participants receiving JNJ 53718678 and 6 participants receiving placebo) and a maximum of 24 participants (16 participants receiving JNJ 53718678 and 8 participants receiving placebo) will be included in this part of the study. Pharmacokinetics and safety of JNJ-53718678 will be evaluated primarily. Participants' safety will be monitored throughout the study.

• Study Type: Interventional
• Enrollment (Actual): 45
• Phase: Phase 1

Contacts and Locations

Study Locations

• Argentina
  • Bahía Blanca, Argentina
  • City of Buenos Aires, Argentina
  • Córdoba, Argentina
• Australia
  • Geelong, Australia
  • Hobart, Australia
  • Westmead, Australia
• Belgium
  • Anderlecht, Belgium
  • Bruxelles, Belgium
  • Charleroi, Belgium
  • Edegem, Belgium
  • Leuven, Belgium
  • Lier, Belgium
• Brazil
  • Curitiba, Brazil
  • Porto Alegre, Brazil
  • Ribeirao Preto, Brazil
  • Rio de Janeiro, Brazil
  • São Paulo, Brazil
• Germany
  • Freiburg, Germany
  • Hamm, Germany
  • Heidelberg, Germany
  • München, Germany
• Netherlands
  • Hoofddorp, Netherlands
  • Utrecht, Netherlands
• Philippines
  • Cebu City, Philippines
  • Manila City, Philippines
• Spain
  • Almeria, Spain
  • Barcelona, Spain
  • Esplugues de Llobregat, Spain
  • Getafe, Spain
  • Madrid, Spain
  • Malaga, Spain
  • Santiago de Compostela, Spain
  • Sevilla, Spain
  • Valencia, Spain
• Sweden
  • Göteborg, Sweden
  • Linköping, Sweden
  • Lund, Sweden
  • Malmö, Sweden
• United States
  • Missouri
    • Kirksville, Missouri, United States

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 month to 2 years (CHILD)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Participant has presented at the hospital for suspected Respiratory Syncytial Virus (RSV) infection within 72 hours prior to Screening completion
• Participant has been hospitalized for this suspected RSV infection
• Participant has been diagnosed with RSV infection using a polymerase chain reaction (PCR)-based assay, preferably commercially available locally
• Participant was born after a normal term pregnancy (greater than or equal to 37 weeks and 0 days)
• A legally acceptable representative of the participant must sign an Informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study, are willing for their child to participate in the study, are willing for their child to remain in the hospital for the first 3 days of dosing (even if not clinically indicated), and are willing/able to adhere to the prohibitions and restrictions specified in the protocol and study procedures

Exclusion Criteria:

• Participant who had major surgery within the 28 days prior to randomization or planned major surgery through the course of the study
• Participant has major congenital anomalies or known cytogenetic disorders
• Participant has known or suspected immunodeficiency, such as known human immunodeficiency virus (HIV) infection
• Participant has known or suspected hepatitis B or C infection
• Participant is upon current admission initially hospitalized in the Intensive care unit (ICU) and/or in need of invasive endotracheal mechanical ventilation

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: DOUBLE

Number of Arms

16

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Part 1: Cohort 1a; Participants (greater than or equal to [>=] 6 months and less than or equal to [<=] 24 months of age) will receive JNJ-53718678, 2 milligram per kilogram body weight (mg/kg) oral solution once daily on Day 1 to Day 7. Dose and/or dosing regimen may be adapted in subsequent cohorts based on the review of the safety/tolerability and full pharmacokinetic data from Cohort 1a.	Drug: JNJ-53718678; JNJ-53718678 oral solution will be administered once or twice daily for 7 days.
EXPERIMENTAL: Part 1: Cohort 1b; Participants (>= 6 months and <= 24 months of age) will receive total daily dose of 6 mg/kg JNJ-53718678 oral solution or placebo [either in once daily [qd] or twice daily [bid]) on Day 1 to Day 7.	Drug: JNJ-53718678; JNJ-53718678 oral solution will be administered once or twice daily for 7 days.; Drug: Placebo; Placebo oral solution will be administered once or twice daily for 7 days.
EXPERIMENTAL: Part 1: Cohort 1c; Participants (>= 6 months and <= 24 months of age) will receive total daily dose of 18 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.	Drug: JNJ-53718678; JNJ-53718678 oral solution will be administered once or twice daily for 7 days.; Drug: Placebo; Placebo oral solution will be administered once or twice daily for 7 days.
EXPERIMENTAL: Part 1: Cohort 1d; Participants (>= 6 months and <= 24 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 1d is optional and may be included at the discretion of the sponsor.	Drug: JNJ-53718678; JNJ-53718678 oral solution will be administered once or twice daily for 7 days.; Drug: Placebo; Placebo oral solution will be administered once or twice daily for 7 days.
EXPERIMENTAL: Part 1: Cohort 1e; Participants (>= 6 months and <= 24 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 1e is optional and may be included at the discretion of the sponsor.	Drug: JNJ-53718678; JNJ-53718678 oral solution will be administered once or twice daily for 7 days.; Drug: Placebo; Placebo oral solution will be administered once or twice daily for 7 days.
EXPERIMENTAL: Part 1: Cohort 2a; Participants (>= 3 months and less than [<] 6 months of age) will receive total daily dose of 1.5 mg/kg JNJ-53718678 oral solution [either in a qd or a bid regimen] on Day 1 to Day 7.	Drug: JNJ-53718678; JNJ-53718678 oral solution will be administered once or twice daily for 7 days.
EXPERIMENTAL: Part 1: Cohort 2b; Participants (>=3 months and < 6 months of age) will receive total daily dose of 4.5 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.	Drug: JNJ-53718678; JNJ-53718678 oral solution will be administered once or twice daily for 7 days.; Drug: Placebo; Placebo oral solution will be administered once or twice daily for 7 days.
EXPERIMENTAL: Part 1: Cohort 2c; Participants (>= 3 months and < 6 months of age) will receive total daily dose of 13.5 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7	Drug: JNJ-53718678; JNJ-53718678 oral solution will be administered once or twice daily for 7 days.; Drug: Placebo; Placebo oral solution will be administered once or twice daily for 7 days.
EXPERIMENTAL: Part 1: Cohort 2d; Participants (>= 3 months and < 6 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 2d is optional and may be included at the discretion of the sponsor.	Drug: JNJ-53718678; JNJ-53718678 oral solution will be administered once or twice daily for 7 days.; Drug: Placebo; Placebo oral solution will be administered once or twice daily for 7 days.
EXPERIMENTAL: Part 1: Cohort 2e; Participants (>= 3 months and < 6 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 2e is optional and may be included at the discretion of the sponsor.	Drug: JNJ-53718678; JNJ-53718678 oral solution will be administered once or twice daily for 7 days.; Drug: Placebo; Placebo oral solution will be administered once or twice daily for 7 days.
EXPERIMENTAL: Part 1: Cohort 3a; Participants (greater than (>) 1 month and < 3 months of age) will receive total daily dose of 1 mg/kg JNJ-53718678 oral solution [either in a qd or a bid regimen] on Day 1 to Day 7.	Drug: JNJ-53718678; JNJ-53718678 oral solution will be administered once or twice daily for 7 days.
EXPERIMENTAL: Part 1: Cohort 3b; Participants (> 1 month and < 3 months of age) will receive total daily dose of 3 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.	Drug: JNJ-53718678; JNJ-53718678 oral solution will be administered once or twice daily for 7 days.; Drug: Placebo; Placebo oral solution will be administered once or twice daily for 7 days.
EXPERIMENTAL: Part 1: Cohort 3c; Participants (> 1 month and < 3 months of age) will receive total daily dose of 9 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.	Drug: JNJ-53718678; JNJ-53718678 oral solution will be administered once or twice daily for 7 days.; Drug: Placebo; Placebo oral solution will be administered once or twice daily for 7 days.
EXPERIMENTAL: Part 1: Cohort 3d; Participants (> 1 month and < 3 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 3d is optional and may be included at the discretion of the sponsor.	Drug: JNJ-53718678; JNJ-53718678 oral solution will be administered once or twice daily for 7 days.; Drug: Placebo; Placebo oral solution will be administered once or twice daily for 7 days.
EXPERIMENTAL: Part 1: Cohort 3e; Participants (> 1 month and < 3 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 3e is optional and may be included at the discretion of the sponsor.	Drug: JNJ-53718678; JNJ-53718678 oral solution will be administered once or twice daily for 7 days.; Drug: Placebo; Placebo oral solution will be administered once or twice daily for 7 days.
EXPERIMENTAL: Part 2: Cohort f; Participants of all age groups will receive daily dose of JNJ-53718678 oral solution or placebo, either in a qd or a bid regimen on Days 1 to 7.	Drug: JNJ-53718678; JNJ-53718678 oral solution will be administered once or twice daily for 7 days.; Drug: Placebo; Placebo oral solution will be administered once or twice daily for 7 days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum Observed Plasma Concentration (Cmax) of JNJ-53718678	The Cmax is the maximum observed plasma concentration.	Days 1, 2 and 3
Trough Plasma Concentration (Ctrough) of JNJ-53718678	The Ctrough is the plasma concentration before dosing or at the end of the dosing interval of any dose other than the first dose in a multiple dosing regimen.	Days 1, 2 and 3
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)	The AUCtau is the measure of the plasma drug concentration from time zero to end of dosing interval.	Days 1, 2 and 3
Total Apparent Clearance (CL/F) of JNJ-53718678	Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.	Days 1, 2 and 3
Apparent Volume of Distribution (Vd/F) of JNJ-53718678	Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vd/F) is influenced by the fraction absorbed.	Days 1, 2 and 3
Number of Participants With Adverse Events	An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.	Up to Follow-up (Day 28)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area Under the Viral Load-time Curve (VL AUC)	VL will be determined by quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR) assay of nasal swabs. The VL AUC (copies. hour/ml) will be calculated based on the trapezoidal method.	Up to Follow-up (Day 28)
Amount of Viral Load Over Time	VL (copies/ml) at each assessment timepoint where a nasal sample is obtained.	Up to Follow-up (Day 28)
Number of viral particles at Peak Viral Load	Peak viral load (copies/ml) is a measure of the maximum number of viral particles present in nasal swabs.	Up to Follow-up (Day 28)
Time To Peak Viral Load	Time (hours) to peak viral load will be reported.	Up to Follow-up (Day 28)
Number of Participants Reaching Undetectability of virus Between First Administration of Study Drug and Day 28	Non-detectability of virus in nasal swabs between first administration of study drug and Day 28 will be reported.	Day 1 to Day 28
Total Number of Respiratory Syncytial Virus (RSV) Hospitalization Days from Admission to Discharge	The total number of Respiratory Syncytial Virus (RSV) hospitalization days from admission to discharge will be reported.	Up to Follow-up (Day 28)
Total RSV Hospitalization Days with Supplemental Oxygen Requirement	The total number of RSV Hospitalization Days with Supplemental Oxygen Requirement will be reported.	Up to Follow-up (Day 28)
The Number of days in Intensive care unit (ICU) due to RSV	The number of days stayed in ICU due to RSV will be reported.	Up to Follow-up (Day 28)
Total Days of non-invasive ventilator support During RSV Hospitalization	The total number of days with non-invasive ventilator support during RSV hospitalization will be reported.	Up to Follow-up (Day 28)
Total Days of Mechanical Ventilation During RSV Hospitalization	The total number of days with Mechanical Ventilation during RSV hospitalization will be reported.	Up to Follow-up (Day 28)
Changes in Peripheral Capillary Oxygen Saturation (SpO2)	The Percentage of Peripheral Capillary Oxygen Saturation (SpO2) will be assessed by the investigator during hospitalisation.	Up to Follow-up (Day 28)
Change from Baseline in Respiratory Rate	The Respiratory rate (number of breaths per minute) will be assessed by the investigator and caregiver during hospitalisation.	Up to Follow-up (Day 28)
Change from Baseline in Body Temperature	The body temperature (degrees Celcius) will be assessed by the investigator and caregiver during hospitalisation.	Up to Follow-up (Day 28)
Clinical Symptom Score	The clinical symptom score will be assessed by the investigator (Clinician Outcome Assessment) and caregiver symptom Diary for each symptom. Clinical Symptom score ranges from 0 (best) to 4 (worst).	Up to Follow-up (Day 28)

Collaborators and Investigators

• Sponsor: Janssen Sciences Ireland UC

Publications and helpful links

General Publications

• Martinon-Torres F, Rusch S, Huntjens D, Remmerie B, Vingerhoets J, McFadyen K, Ferrero F, Baraldi E, Rojo P, Epalza C, Stevens M. Pharmacokinetics, Safety, and Antiviral Effects of Multiple Doses of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678, in Infants Hospitalized With RSV Infection: A Randomized Phase 1b Study. Clin Infect Dis. 2020 Dec 17;71(10):e594-e603. doi: 10.1093/cid/ciaa283.

Study record dates

Study Major Dates

• Study Start (ACTUAL): December 4, 2015
• Primary Completion (ACTUAL): March 21, 2017
• Study Completion (ACTUAL): November 10, 2017

Study Registration Dates

• First Submitted: August 21, 2015
• First Submitted That Met QC Criteria: October 30, 2015
• First Posted (ESTIMATE): November 1, 2015

Study Record Updates

• Last Update Posted (ACTUAL): December 6, 2019
• Last Update Submitted That Met QC Criteria: December 5, 2019
• Last Verified: December 1, 2019

More Information

Terms related to this study

• Keywords: Infants; Placebo; Respiratory Syncytial Virus Infections; JNJ-53718678
• Additional Relevant MeSH Terms: Pathologic Processes; RNA Virus Infections; Disease Attributes; Paramyxoviridae Infections; Mononegavirales Infections; Pneumovirus Infections; Infections; Communicable Diseases; Virus Diseases; Respiratory Syncytial Virus Infections
• Other Study ID Numbers: CR107945; 2015-002003-28 (EUDRACT_NUMBER); 53718678RSV1005 (OTHER: Janssen Sciences Ireland UC)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes